Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 52-Week Low – What’s Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week low on Tuesday . The company traded as low as $27.84 and last traded at $28.09, with a volume of 59143 shares changing hands. The stock had previously closed at $28.44.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on COLL shares. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler lowered their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Stock Down 1.4 %

The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a market cap of $904.29 million, a price-to-earnings ratio of 12.09 and a beta of 0.82. The stock’s 50-day moving average is $30.81 and its 200-day moving average is $33.39.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.98% of the stock is owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in COLL. Invesco Ltd. boosted its stake in Collegium Pharmaceutical by 19.5% during the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock valued at $50,876,000 after purchasing an additional 289,335 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after buying an additional 64,958 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Collegium Pharmaceutical by 0.3% during the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company’s stock worth $47,603,000 after buying an additional 5,480 shares in the last quarter. Geode Capital Management LLC raised its position in Collegium Pharmaceutical by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock valued at $29,974,000 after buying an additional 5,464 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock valued at $29,586,000 after buying an additional 116,327 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.